Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Objective To examine the metabolic effects and body composition changes after topiramate treatment of obese type 2 diabetic patients (DM2) for 11 months. Design and subjects Thirty-eight DM2 on diet or sulfonylurea treatment participated in this randomized double-blind placebo-controlled trial. Thirteen placebo-treated and nine topiramate-treated patients completed the trial. Patients were randomized to treatment with topiramate 96 mg b.i.d. or placebo (6-week run-in phase, 2-months titration phase, 9-months maintenance phase). Measurements Insulin sensitivity was measured with euglycaemic hyperinsulinemic clamps. Weight, HbA1c, fasting glucose, blood lipids and safety variables were measured at regular intervals. Body composition was determined with computerized tomography. Meal tests were performed to evaluate postprandial glucose and insulin levels. Three-day diet recalls were carried out to evaluate energy ingestion. Results The mean age was 58.6+/-7.1 years, body weight 98.1+/-16.1 kg, BMI 33.0+/-4.5 kg/m(2), and glycosylated hemoglobin (HbA1c) 7.3+/-0.9%. In topiramate-treated patients, there were significant reductions in HbA1c (1.1+/-0.9%), fasting plasma glucose, body weight (-6.6+/-3.3%), as well as body fat, lean body mass, postprandial glucose and free fatty acid levels but there were no significant changes in insulin sensitivity. The daily average energy intake decreased more in the topiramate group than in the placebo group. Paresthesia and central nervous syste…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Topiramate negatively affects BMD383 but might not affect lean mass384,385.”
From Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies (2018) · cites this paper as [384]
Citations
Cites
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review
Inzucchi, S. E. (2002) · JAMA · doi:10.1001/jama.287.3.360 · Cited by 1,065 · cited 3×
“Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial B Eliasson1, S Gudbjörnsdottir1, J Cederholm2, Y Liang3, F Vercruysse4 and U Smith1 1Lundberg Laboratory for Diabetes Research, Sahlgrenska University Hospital, Göteborg…”
BackgroundInfluentialPetersen, K. F., Dufour, S., Befroy, D., Lehrke, M., Hendler, R. E., & Shulman, G. I. (2005) · Diabetes · doi:10.2337/diabetes.54.3.603 · Cited by 911
Kvist, H., Chowdhury, B., Grangård, U., Tylén, U., & Sjöström, L. (1988) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/48.6.1351 · Cited by 794
Determination of total adipose tissue and body fat in women by computed tomography, 40K, and tritium
Sjostrom, L., Kvist, H., Cederblad, A., & Tylen, U. (1986) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1986.250.6.e736 · Cited by 368
Bray, G. A., Hollander, P., Klein, S., Kushner, R., Levy, B., Fitchet, M., & Perry, B. H. (2003) · Obesity Research · doi:10.1038/oby.2003.102 · Cited by 344
Sopasakis, V. R., Sandqvist, M., Gustafson, B., Hammarstedt, A., Schmelz, M., Yang, X., Jansson, P., & Smith, U. (2004) · Obesity Research · doi:10.1038/oby.2004.51 · Cited by 243
Self-citationTopiramate vs placebo in painful diabetic neuropathy: Analgesic and metabolic effects
Raskin, P., Donofrio, P. D., Rosenthal, N. R., Hewitt, D. J., Jordan, D. M., Xiang, J., & Vinik, A. I. (2004) · Neurology · doi:10.1212/01.wnl.0000137341.89781.14 · Cited by 239
for the OBES-002 Study Group, Wilding, J., Gaal, L. V., Rissanen, A., Vercruysse, F., & Fitchet, M. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802783 · Cited by 224
Self-citationPredictors of Weight Loss in Adults with Topiramate‐Treated Epilepsy
Ben‐Menachem, E., Axelsen, M., Johanson, E. H., Stagge, A., & Smith, U. (2003) · Obesity Research · doi:10.1038/oby.2003.78 · Cited by 202
Self-citation
Cited by
Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies
Batsis, J. A., & Villareal, D. T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0062-9 · Cited by 1,382
Efficacy and safety of topiramate on weight loss: a meta‐analysis of randomized controlled trials
Kramer, C. K., Leitão, C. B., Pinto, L. C., Canani, L. H., Azevedo, M. J., & Gross, J. L. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2010.00846.x · Cited by 323
“Eliasson B, 2007 (39) BMI 27 kg m-2 and type 2 diabetes on diet”
BackgroundThe Evidence for Medical Nutrition Therapy for Type 1 and Type 2 Diabetes in Adults
Franz, M. J., Powers, M. A., Leontos, C., Holzmeister, L. A., Kulkarni, K., Monk, A., Wedel, N., & Gradwell, E. (2010) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2010.09.014 · Cited by 306
Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes
Scheen, A. J., & Van Gaal, L. F. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70004-x · Cited by 190
Central control of thermogenesis
Clapham, J. C. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.10.014 · Cited by 140
“…noted as a side effect in clinical trials for topiramate (Guerrini and Parmeggiani, 2006) and subsequent studies with body weight as an endpoint indicated that topiramate may be useful in the treatment of obesity (Astrup et al., 2004; Bray et al., 2003; Eliasson et al., 2007; Kramer et al., 2011).”
Metadata
- Authors
- Eliasson, B., Gudbjörnsdottir, S., Cederholm, J., Liang, Y., Vercruysse, F., & Smith, U.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Uppsala University Hospital (SE)
- Janssen Research & Development (United States) (US)
- Corresponding author
- Eliasson, B
- Venue
- International Journal of Obesity
- Published
- 2007-02-13
- Volume
- 31
- Issue
- 7
- Pages
- 1140-1147
- ISSN
- 0307-0565 (ISSN-L)
- 1476-5497
- OpenAlex
- W2052347592
- Cited by
- 57
- References
- 22
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 5 · 2023: 3 · 2022: 2 · 2021: 1 · 2018: 1 · 2017: 2 · 2016: 2 · 2015: 2 · 2014: 6 · 2013: 6 · 2012: 3
- FWCI
- 3.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- International Journal of Obesity (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- topiramate, type 2 diabetes, obesity, weight loss, body composition, insulin sensitivity, glycemic control, HbA1c, fat mass, energy intake, postprandial blood glucose, insulin secretion, adverse effects
- MeSH terms
- Topiramate, Adult, Aged, Body Composition, Cells, Cultured, Diabetes Mellitus, Type 2, Dietary Fats, Double-Blind Method, Drug Therapy, Combination, Female, Fructose, Humans, Hypoglycemic Agents, Insulin Resistance, Male, Middle Aged, Obesity, Placebos, Sulfonylurea Compounds, Weight Loss, Cytokines, Adipocytes, Anti-Obesity Agents, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.